220 related articles for article (PubMed ID: 32406600)
1. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis.
Yamamoto Y; Matsusaka K; Fukuyo M; Rahmutulla B; Matsue H; Kaneda A
Cancer Med; 2020 Oct; 9(19):7194-7204. PubMed ID: 32406600
[TBL] [Abstract][Full Text] [Related]
2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
3. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
4. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.
Hou P; Liu D; Dong J; Xing M
Cell Cycle; 2012 Jan; 11(2):286-95. PubMed ID: 22189819
[TBL] [Abstract][Full Text] [Related]
5. DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
Koroknai V; Szász I; Hernandez-Vargas H; Fernandez-Jimenez N; Cuenin C; Herceg Z; Vízkeleti L; Ádány R; Ecsedi S; Balázs M
Exp Dermatol; 2020 Jan; 29(1):39-50. PubMed ID: 31602702
[TBL] [Abstract][Full Text] [Related]
6. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients.
Li X; Cai Y
Aging (Albany NY); 2020 Aug; 12(16):16457-16475. PubMed ID: 32858528
[TBL] [Abstract][Full Text] [Related]
8. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
[TBL] [Abstract][Full Text] [Related]
9. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
12. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer.
Takane K; Akagi K; Fukuyo M; Yagi K; Takayama T; Kaneda A
Cancer Med; 2017 May; 6(5):1023-1035. PubMed ID: 28378457
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma.
Mazar J; Khaitan D; DeBlasio D; Zhong C; Govindarajan SS; Kopanathi S; Zhang S; Ray A; Perera RJ
PLoS One; 2011; 6(9):e24922. PubMed ID: 21949788
[TBL] [Abstract][Full Text] [Related]
16. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
Forloni M; Dogra SK; Dong Y; Conte D; Ou J; Zhu LJ; Deng A; Mahalingam M; Green MR; Wajapeyee N
Elife; 2014 Feb; 3():e01460. PubMed ID: 24550252
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation characteristics of primary melanomas with distinct biological behaviour.
Ecsedi S; Hernandez-Vargas H; Lima SC; Vizkeleti L; Toth R; Lazar V; Koroknai V; Kiss T; Emri G; Herceg Z; Adany R; Balazs M
PLoS One; 2014; 9(5):e96612. PubMed ID: 24832207
[TBL] [Abstract][Full Text] [Related]
19. Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
Quan VL; Zhang B; Zhang Y; Mohan LS; Shi K; Wagner A; Kruse L; Taxter T; Beaubier N; White K; Zou L; Gerami P
J Invest Dermatol; 2020 Aug; 140(8):1599-1608. PubMed ID: 32004563
[TBL] [Abstract][Full Text] [Related]
20. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.
Hoshimoto S; Kuo CT; Chong KK; Takeshima TL; Takei Y; Li MW; Huang SK; Sim MS; Morton DL; Hoon DS
J Invest Dermatol; 2012 Jun; 132(6):1689-97. PubMed ID: 22402438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
